544009

Blue Jet Healthcare described FY26 as a foundational year with significant investments, despite a decline in overall revenue and muted EBITDA primarily due to PI/API destocking. For FY27, management guided for double-digit growth in the contrast media segment, driven by 3-4 new product launches and backward integration. The PI segment is expected to recover and exceed FY25 peak levels as inventory destocking normalizes. The company plans a capex of approximately INR 1,000 crores over 3 years for the Vizag greenfield project and INR 40 crores for a new Hyderabad R&D center, targeting peptide-related intermediates and GLP-1 opportunities. Blue Jet Healthcare remains debt-free with strong liquidity, expecting improved business visibility and commercialization of new products in FY27.

Blue Jet Healthcare Limited has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report, issued by Mehta and Mehta, Company Secretaries, confirms the company's full compliance with all applicable SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other relevant SEBI regulations and secretarial standards. No non-compliances, regulatory actions, or auditor resignations were observed during the review period.